Dropout · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Outcomes (2‐6 months post‐treatment) · adults with panic disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder
Selective serotonin reuptake inhibitors may leads to lower failure to respond compared with placebo (low certainty).
1 finding from 1 review
Leaving the study early · adults with panic disorder
Selective serotonin reuptake inhibitors showed no clear difference in total number of dropouts compared with placebo (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · adults with panic disorder
Selective serotonin reuptake inhibitors probably leads to lower failure to remit compared with placebo (moderate certainty).
1 finding from 1 review
panic symptoms · adults with panic disorder
2 findings from 1 review
Withdrawals due to adverse events · adults with panic disorder
Selective serotonin reuptake inhibitors probably leads to higher number of dropouts due to adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Subjective sleep quality or quantity · adults with insomnia
1 finding from 1 review
Other subjective measures of sleep (total sleep time, sleep onset latency, nocturnal awakenings and subjective sleep efficiency) (PSQI) (at 12 weeks) · adults with insomnia
1 finding from 1 review
Adverse events (at 12 weeks) · adults with insomnia
1 finding from 1 review
PSG sleep outcomes (at 12 weeks) · adults with insomnia
1 finding from 1 review